OctaGenix® was formed with the core premise of meeting patient needs in clear-cut cases where there have been deficiencies. The first two areas, dealing with obesity and its inherent consequences, and secondly the application of medicinal cannabis, have more recently been followed by some truly innovative solutions towards the stem of the COVID-19 pandemic.
OctaGenix® - our response to the global COVID-19 pandemic
With global infection cases edging over 44 million and deaths well in excess of a million people, Covid-19 is having an unprecedented impact across the world.
At OctaGenix® we know that if critical steps are not taken to deal with the COVID-19 pandemic, it will lead to extensive deaths. We estimate that COVID-19 can infect over 250 million people Worldwide and death rates can be as high as 6 million plus. These figures can fluctuate greatly depending on the success and effectiveness of testing targets, social distancing, and enforcement of directives.
Viruses are more intelligent than us human beings, COVID-19 can further mutate and will kill the most vulnerable people.COVID – 19 and Our Response
Our organisation comprises some of the World’s top researchers and scientists, with some of the big drug discoveries and research attached to their names. In February 2020, we exactly knew what was coming and fully anticipated the range of impacts,hence we felt the onus to contribute in the battle against the COVID-19 pandemic. On the 4th of February 2020, two of our Directors Dr. Thomas Brian Chapman and Mr. Zulfiqar Khan, contacted the Department of Health and Social Care to discuss their concerns about the pandemic. Both gentlemen knew the impending dangers of COVID-19 and emphasised the need for NHS trusts to be more proactive rather than reactive to the COVID-19 pandemic threats.
Artemisinin and COVID-19 Study
We estimated that a vaccine could well be freely available after March 2021, but we cannot wait for the virus to claim thousands’ more lives, therefore we are in the process of setting-up a clinical study with Artemisinin to save lives of the infected COVID-19 patients.
Based on the anti-Inflammatory and immunoregulatory properties of Artemisinin, our scientists and clinical study co-ordinators have registered the first clinical trials with Artemisinin in the infected COVID-19 population, with the scope of saving thousands of lives.
We believe a drug such as Artemisinin, with a proven anti-viral track record, with an anti-Inflammatory and immunoregulatory effect, can be beneficial to COVID-19 patients.
COVID -19 Projects
iSMART® – A fully integrated system
We are pleased to bring a pragmatic solution to the world against the global COVID-19 pandemic by invention of our "state of the art" British technology that will act as "The First Line of Defence" against COVID 19. We call this fully patented system "iSMART".iSMART- A patented system like no other!
The iSMART system is the first and ONLY 5-in-1 System invented by OctaGenix® to halt the spread of Covid-19 across the UK and globally. The iSMART system; is designed to support the "Track and Trace" App with detailed and accurate Data to complement local and global initiatives to combat the virus.Anti-viral Mechanism of Artemisinin and its Derivatives
Artemisinin is a sesquiterpene lactone containing a peroxide bridge. This peroxide bridge plays an essential role in antimalarial pathways for artemisinin (O’Neill, Barton and Ward, 2010). Several mechanistic models have been proposed, but it is broadly accepted that artemisinin exerts antimalarial effects through the following molecular mechanisms: Haem or free iron will break the peroxide bridge, which results in the metabolism of the molecular structure of artemisinin to form nucleophilic radical metabolites with a high affinity for malarial parasites which are rich in hemin (Meshnick et al., 1991; O’Neill, Barton and Ward, 2010). Consequently, the “free radicals”, acting as an alkylating agent, will attack macromolecular bearing electrophilic groups or centres. Through this transformation, Artemisinin targets malarial mitochondria and directly impairs their function (Wang et al., 2010).
Anti-Inflammation and Immunoregulatory Effects of Artemisinin
The hyperinflammation observed in Covid-19 patients has seen calls for the identification of pre-approved therapies with proven safety profiles to address the immediate need of rising mortality (Mehta et al., 2020). Artemisinin and its derivatives provide this opportunity. Artemisinin’s possess wide ranging immunomodulatory effects on immune cell responses, supressing secretion of cytokines, decreasing neutrophil counts, reductions in macrophage activity and inhibiting lymphocyte proliferation and maintenance (Yao, Wang and Wang, 2016). Artemisinin and its derivatives have high anti-viral efficacy and similar potency in multi-drug resistant areas where their combination with other anti-malarial is highly promising (Balint, 2001).
Wang et al. demonstrated the immunosuppressive effects of artemether which significantly suppressed the proliferation and IL-2 and interferon-γ (IFN-γ) production of T cells triggered by T cell receptor (TCR) engagement (Wang et al., 2007). Artemether significantly inhibited TCR engagement-triggered MAPKs signalling pathway including phosphorylation of ERK1/2, Jnk, and P38. Artemether majorly affected the function of T cells, rather than the antigen-presenting cells (APCs) to exert the immunosuppressive effects (Shi et al., 2015)
Recents Posts
i-SMART® Ultimate
i-SMART® Ultimate iSMART® Ultimate is invented by the top scientists – for its suitability to control the spread of infection within regions, counties, and boroughs…
Artemisinin and COVID-19 Study
Artemisinin and COVID-19 Study We estimated that a vaccine could well be freely available after March 2021, but we cannot wait for the virus to…
COVID – 19 and Our Response
COVID – 19 and Our Response Our organisation comprises some of the World’s top researchers and scientists, with some of the big drug discoveries and…
COVID-19 Explained
Key stages of the Sars-CoV-2 life cycle SARS-CoV-2 the causative agent of COVID-19 is a member of the highly diverse coronavirus family, named for the…
